Zenas BioPharma Financial Ratios
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.26+1.02 (+3.89%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zenas BioPharma ratio analysis
Zenas BioPharma earned a net margin of -3777.4% in FY 2025, down from -3139.8% a year earlier. Return on equity reached -156.0%, meaning Zenas BioPharma generated -1.56 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.32, and the current ratio was 5.61.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Zenas BioPharma financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Price / sales | 154.32 | 25.95 | — |
| Price / book | 6.37 | 0.42 | — |
| Operating margin | -3,830.6% | -3,277.8% | -74.3% |
| Net margin | -3,777.4% | -3,139.8% | -74.2% |
| Free cash flow margin | -1,723.5% | -2,396.1% | -61.1% |
| Return on equity (ROE) | -156.0% | -50.2% | — |
| Return on assets (ROA) | -98.5% | -42.4% | -54.4% |
| Debt / equity | 0.32 | — | — |
| Current ratio | 5.61 | 6.21 | 2.57 |
| Revenue growth | 100.0% | -90.0% | — |